• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Ingevity Corporation

    3/31/25 7:01:43 AM ET
    $NGVT
    Major Chemicals
    Industrials
    Get the next $NGVT alert in real time by email
    DEFA14A 1 ef20046475_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 14A
     
    Proxy Statement Pursuant to Section 14(a)
    of the Securities Exchange Act of 1934
    (Amendment No.      )

    Filed by the Registrant   ☒

    Filed by a party other than the Registrant   ☐

    Check the appropriate box:
     
    ☐
    Preliminary Proxy Statement

    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐
    Definitive Proxy Statement

    ☒
    Definitive Additional Materials

    ☐
    Soliciting Material Pursuant to §240.14a-12

    INGEVITY CORPORATION

    (Name of Registrant as Specified In Its Charter)
     

    (Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)
     
    Payment of Filing Fee (Check the appropriate box):
     
    ☒
    No fee required.
    ☐
    Fee paid previously with preliminary materials.
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



    On March 30, 2025, Ingevity Corporation (the “Company”) filed a Current Report on Form 8-K (the “Cooperation Agreement 8-K”) with the Securities and Exchange Commission (the “SEC”) disclosing its entry into a Cooperation Agreement with Vision One Fund, LP and certain of its affiliates. The Company is filing this Form DEFA14A on Schedule 14A to update the Company’s Definitive Proxy Statement (the “Proxy Statement”) filed with the SEC on March 20, 2025 with the information contained in the Cooperation Agreement 8-K. The below information supplements, and should be read in conjunction with, the Proxy Statement.



    Item 1.01
    Entry Into a Material Definitive Agreement.

    Cooperation Agreement

    On March 30, 2025, Ingevity Corporation (the “Company”) entered into a cooperation agreement (the “Cooperation Agreement”) with Vision One Fund, LP and certain of its affiliates (the “Vision One Parties”).

    Pursuant to the Cooperation Agreement, the Company agreed to (i) appoint F. David Segal to the Company’s Board of Directors (the “Board”) within one day of the 2025 annual meeting of stockholders (the “2025 Annual Meeting”), (ii) appoint Mr. Segal to the Audit Committee of the Board and (iii) not increase the size of the Board to more than eleven directors until the earliest date pursuant to which stockholder nominations for director elections are permitted to be delivered pursuant to the Company’s bylaws for the Company’s 2026 annual meeting of stockholders (the “Expiration Date”). The Cooperation Agreement provides that the Company and Vision One parties will cooperate in good faith to select a mutually agreeable replacement director in the event that Mr. Segal ceases to serve as a director before the Expiration Date.

    Pursuant to the Cooperation Agreement, the Vision One Parties agreed to withdraw their nominees for the 2025 Annual Meeting and to abide by certain customary standstill restrictions, mutual non-disparagement provisions, voting commitments, including supporting each director nominated and recommended by the Board for election, and other obligations until the Expiration Date.

    The foregoing description of the Cooperation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Cooperation Agreement, a copy of which is attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on March 30, 2025.



    Get the next $NGVT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NGVT

    DatePrice TargetRatingAnalyst
    2/26/2025$62.00 → $65.00Market Perform → Outperform
    BMO Capital Markets
    8/7/2024$58.00Market Perform → Market Outperform
    CJS Securities
    4/22/2024$52.00 → $62.00Hold → Buy
    Jefferies
    11/6/2023$49.00Market Outperform → Market Perform
    CJS Securities
    10/3/2023$62.00 → $53.00Buy → Hold
    Loop Capital
    8/7/2023$71.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/27/2023$64.00 → $75.00Hold → Buy
    Loop Capital
    5/5/2023$92.00 → $64.00Buy → Hold
    Loop Capital
    More analyst ratings

    $NGVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ingevity upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Ingevity from Market Perform to Outperform and set a new price target of $65.00 from $62.00 previously

    2/26/25 7:15:06 AM ET
    $NGVT
    Major Chemicals
    Industrials

    Ingevity upgraded by CJS Securities with a new price target

    CJS Securities upgraded Ingevity from Market Perform to Market Outperform and set a new price target of $58.00

    8/7/24 9:18:13 AM ET
    $NGVT
    Major Chemicals
    Industrials

    Ingevity upgraded by Jefferies with a new price target

    Jefferies upgraded Ingevity from Hold to Buy and set a new price target of $62.00 from $52.00 previously

    4/22/24 7:39:26 AM ET
    $NGVT
    Major Chemicals
    Industrials

    $NGVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Finance & CAO Platt Phillip John covered exercise/tax liability with 1,444 shares, decreasing direct ownership by 5% to 28,243 units (SEC Form 4)

    4 - Ingevity Corp (0001653477) (Issuer)

    8/13/25 4:25:16 PM ET
    $NGVT
    Major Chemicals
    Industrials

    SVP, Gen. Counsel & Secretary Fisher Ryan C. covered exercise/tax liability with 169 shares, decreasing direct ownership by 1% to 14,758 units (SEC Form 4)

    4 - Ingevity Corp (0001653477) (Issuer)

    7/9/25 9:23:04 AM ET
    $NGVT
    Major Chemicals
    Industrials

    Director Willis J Kevin was granted 620 shares, increasing direct ownership by 9% to 7,794 units (SEC Form 4)

    4 - Ingevity Corp (0001653477) (Issuer)

    7/3/25 12:38:40 PM ET
    $NGVT
    Major Chemicals
    Industrials

    $NGVT
    SEC Filings

    View All

    SEC Form 10-Q filed by Ingevity Corporation

    10-Q - Ingevity Corp (0001653477) (Filer)

    8/5/25 4:45:46 PM ET
    $NGVT
    Major Chemicals
    Industrials

    Ingevity Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Ingevity Corp (0001653477) (Filer)

    8/4/25 4:27:48 PM ET
    $NGVT
    Major Chemicals
    Industrials

    Ingevity Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Ingevity Corp (0001653477) (Filer)

    7/1/25 6:46:15 AM ET
    $NGVT
    Major Chemicals
    Industrials

    $NGVT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ingevity reports second quarter 2025 financial results

    HIGHLIGHTS: Net sales of $365.1 million, down 7% compared to prior year, primarily due to lower sales in Performance Chemicals Net loss of $146.5 million and diluted loss per share of $4.02 included an Advanced Polymer Technologies pre-tax non-cash goodwill impairment charge of $183.8 million Adjusted earnings of $51.1 million were up 39% and diluted adjusted earnings per share of $1.39 was up 38% Adjusted EBITDA of $110.0 million increased 9% and adjusted EBITDA margin improved to 30.1% primarily due to the successful execution of repositioning actions in Performance Chemicals Operating cash flow of $79.0 million with free cash flow of $66.8 million Ingevity raises the lo

    8/4/25 4:15:00 PM ET
    $NGVT
    Major Chemicals
    Industrials

    Ingevity named one of America's Best Mid-sized Companies by TIME

    Ingevity Corporation (NYSE:NGVT) today announced it has been named one of "America's Best Mid-Size Companies 2025" by TIME Magazine and Statista. This award recognizes 500 top-performing U.S. companies with revenues between $100 million and $10 billion that demonstrate strong performance amid a rapidly evolving economic landscape. "Ingevity is proud to receive this acknowledgement for our excellence in prioritizing people and purpose," said Dave Li, Ingevity president and CEO. "This recognition reflects our team's dedication to operating responsibly, supporting our communities and delivering long-term value for our stakeholders." Ingevity's ranking was based on a combination of direct a

    7/22/25 11:00:00 AM ET
    $NGVT
    Major Chemicals
    Industrials

    Ingevity announces dates for second-quarter 2025 earnings release and webcast

    Ingevity Corporation (NYSE:NGVT) announced today that it will release its second-quarter 2025 earnings after the stock market close on Monday, August 4, 2025. The company will host a live webcast on Tuesday, August 5, at 10:00 a.m. (Eastern) to discuss second-quarter 2025 fiscal results. The webcast can be accessed here or on the investors section of Ingevity's website. Participants may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 590026. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on August 5, 2

    7/22/25 9:00:00 AM ET
    $NGVT
    Major Chemicals
    Industrials

    $NGVT
    Financials

    Live finance-specific insights

    View All

    Ingevity reports second quarter 2025 financial results

    HIGHLIGHTS: Net sales of $365.1 million, down 7% compared to prior year, primarily due to lower sales in Performance Chemicals Net loss of $146.5 million and diluted loss per share of $4.02 included an Advanced Polymer Technologies pre-tax non-cash goodwill impairment charge of $183.8 million Adjusted earnings of $51.1 million were up 39% and diluted adjusted earnings per share of $1.39 was up 38% Adjusted EBITDA of $110.0 million increased 9% and adjusted EBITDA margin improved to 30.1% primarily due to the successful execution of repositioning actions in Performance Chemicals Operating cash flow of $79.0 million with free cash flow of $66.8 million Ingevity raises the lo

    8/4/25 4:15:00 PM ET
    $NGVT
    Major Chemicals
    Industrials

    Ingevity announces dates for second-quarter 2025 earnings release and webcast

    Ingevity Corporation (NYSE:NGVT) announced today that it will release its second-quarter 2025 earnings after the stock market close on Monday, August 4, 2025. The company will host a live webcast on Tuesday, August 5, at 10:00 a.m. (Eastern) to discuss second-quarter 2025 fiscal results. The webcast can be accessed here or on the investors section of Ingevity's website. Participants may also listen to the conference call by dialing 833 470 1428 (inside the U.S.) and entering access code 590026. Callers outside the U.S. can find global dial-in numbers here. For those unable to join the live event, a recording will be available beginning at approximately 2:00 p.m. (Eastern) on August 5, 2

    7/22/25 9:00:00 AM ET
    $NGVT
    Major Chemicals
    Industrials

    Ingevity reports first quarter 2025 financial results

    HIGHLIGHTS: Net sales of $284.0 million, down 17% compared to prior year, primarily due to repositioning actions in Performance Chemicals, which included the exit of certain lower-margin end markets Net income of $20.5 million and diluted earnings per share (EPS) of $0.56 reflects before-tax special charges of $20.2 million; adjusted earnings of $36.4 million and diluted adjusted EPS of $0.99 Adjusted EBITDA of $91.3 million increased 23% and adjusted EBITDA margin improved to 32.1% due primarily to the successful execution of repositioning actions in Performance Chemicals and continued strong profitability in Performance Materials Operating cash flow of $25.4 million with free cash

    5/5/25 4:15:00 PM ET
    $NGVT
    Major Chemicals
    Industrials

    $NGVT
    Leadership Updates

    Live Leadership Updates

    View All

    Ingevity announces departure of Performance Materials segment president, Ed Woodcock

    Ingevity Corporation (NYSE:NGVT) today announced Ed Woodcock, executive vice president and president, Performance Materials, departed the company effective July 1, 2025. Woodcock's departure follows a 37-year career with the company. "Ed Woodcock's leadership has been foundational to the successful growth of Ingevity's Performance Materials activated carbon business as the industry leader in automotive emissions capture," said Ingevity president and CEO, Dave Li. "During his extensive career with the company, Ed drove global expansion of the business, delivered consistently strong profitability and positioned the Performance Materials segment for growth in the hybrid and electric vehicle

    7/1/25 6:30:00 AM ET
    $NGVT
    Major Chemicals
    Industrials

    Ingevity Files Definitive Proxy Statement and Issues Letter to Stockholders

    Board and Management Team Have Taken Significant and Decisive Action to Respond to External Market Challenges Key Transformational Changes Are Driving Strong Financial Results and Stock Price Outperformance Continued Execution of Proven Strategy Positions Ingevity to Unlock Significant Additional Stockholder Value Company Urges Stockholders to Vote "FOR" ONLY Ingevity's Highly Qualified Director Nominees on the WHITE Proxy Card Launches VoteIngevity.com Providing Additional information for Stockholders Ingevity Corporation (NYSE:NGVT) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its 2025 Annual Meet

    3/20/25 5:34:00 PM ET
    $NGVT
    Major Chemicals
    Industrials

    Ingevity announces appointment of David H. Li as president and CEO

    Li brings 25-year+ record of driving successful corporate transformation, long-term growth and stockholder value creation at premier global specialty materials supplier Ingevity Corporation (NYSE:NGVT) today announced that its board of directors has appointed David H. Li as the company's president and CEO, effective as of April 7, 2025, and that he is expected to join the board of directors following the 2025 Annual Meeting. Li succeeds Ingevity board member, Luis Fernandez-Moreno, who has been serving as interim president and CEO since October 2024. Fernandez-Moreno will remain on Ingevity's board. This press release features multimedia. View the full release here: https://www.businesswir

    3/10/25 4:15:00 PM ET
    $NGVT
    Major Chemicals
    Industrials

    $NGVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ingevity Corporation

    SC 13G/A - Ingevity Corp (0001653477) (Subject)

    11/12/24 3:54:24 PM ET
    $NGVT
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Ingevity Corporation

    SC 13G/A - Ingevity Corp (0001653477) (Subject)

    11/4/24 11:52:25 AM ET
    $NGVT
    Major Chemicals
    Industrials

    SEC Form SC 13D/A filed by Ingevity Corporation (Amendment)

    SC 13D/A - Ingevity Corp (0001653477) (Subject)

    2/28/24 5:30:32 PM ET
    $NGVT
    Major Chemicals
    Industrials